

Serlopitant found to be safe, effective for chronic pruritus

April 24 2018



(HealthDay)—Serlopitant has potential as a therapy for the treatment of

chronic pruritus, according to a study published in the May issue of the *Journal of the American Academy of Dermatology*.

Gil Yosipovitch, M.D., from the University of Miami, and colleagues assessed the safety and efficacy of the P/neurokinin 1 receptor antagonist serlopitant in treating chronic pruritus among patients with severe chronic pruritus who were unresponsive to antihistamines or topical steroids. Patients were randomized to either serlopitant (0.25, 1, or 5 mg) or placebo. Serlopitant was administered once daily for six weeks as monotherapy or with mid-potency steroids and emollients.

The researchers found that serlopitant treatment resulted in a dose-dependent decrease in pruritus. The decreases from baseline using visual analogue scale pruritus scores were statistically significantly larger with the 1- and 5-mg doses of serlopitant ($P = 0.022$ and 0.013 , respectively) versus placebo at week six. There were no significant safety or tolerability issues observed.

"Serlopitant, 1 mg and 5 mg daily, was associated with a statistically significant reduction in chronic pruritus and was well tolerated," the authors write.

Several authors disclosed [financial ties](#) to pharmaceutical companies, including Menlo Therapeutics, which manufactures serlopitant and supported the study.

More information: [Abstract/Full Text](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: Serlopitant found to be safe, effective for chronic pruritus (2018, April 24) retrieved 17 May 2023 from <https://medicalxpress.com/news/2018-04-serlopitant-safe-effective-chronic->

[pruritus.html](#)

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.